Medication info
Tuberol 60/5 mg (Pimasartan Potassium, Rosuvastatin)

Tuberol 60/5 mg (Pimasartan Potassium, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Fimasartan Potassium Trihydrate Granules›150mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Boryung Pharmaceutical Co., Ltd.
Appearance
Yellow, convex, octagonal film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP packaging ×3], 100 tablets/box [10 tablets/PTP packaging ×10], 30 tablets/box [10 tablets/Alu-Alu packaging ×3], 100 tablets/box [10 tablets/Alu-Alu packaging ×10]
Approval status
Active

MFDS item code 201605334 · Approved 2016.08.31 · Insurance code 641906540

Summary

Main use
Treatment of hypertension; improves dyslipidemia; inhibits the progression of atherosclerosis and reduces cardiovascular disease risk
Who takes it
Adults
Adult dose
This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan and rosuvastatin. ○ Fimasartan 1. Adults The recommended dose of this drug is 30~60 milligrams once daily, with or without food. If blood pressure is not adequately controlled at this dose, it may be increased to 120 milligrams once daily. If possible, it is recommended that the drug be taken at the same time each day (e.g., in the morning). The blood pressure-lowering effect appears within 2 weeks after starting treatment, with the maximum effect occurring at approximately 8 weeks~12 weeks. 2. Older adults No initial dose adjustment is necessary in older adults 70 years of age or younger. (See section 9. Administration to older adults under Precautions for Use.) 3. Patients with renal impairment No dose adjustment is necessary in patients with mild~moderate renal impairment (creatinine clearance 30~80 mL/min). For patients with severe renal impairment (creatinine clearance < 30 mL/min), start treatment at 30 milligrams once daily and do not exceed 60 milligrams daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. Do not administer this drug to patients with moderate~severe hepatic impairment (see section 2. Patients in whom the drug must not be administered and section 10. Administration to patients with hepatic impairment under Precautions for Use). 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 milligrams once daily is recommended. (See section 3. Patients in whom the drug should be used with caution under Precautions for Use.) ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this drug at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of this drug at a dose of 40 milligrams is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Boryung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension; improves dyslipidemia; inhibits the progression of atherosclerosis and reduces cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • hypercholesterolemia.
View approved original text

This medication is prescribed for patients using two drugs, Pimasartan and Rosuvastatin, simultaneously. Pimasartan helps in controlling blood pressure in patients with essential hypertension. Rosuvastatin is used as an adjunctive treatment when dietary changes and exercise fail to control various dyslipidemias including hypercholesterolemia and hyperlipidemia. It is also effective in delaying the progression of atherosclerosis and reducing the risk of cardiovascular diseases, particularly contributing to a decrease in the risk of stroke, myocardial infarction, and arterial revascularization. Through these combined effects, it helps improve patients' cardiovascular health.

How to take

Adult dose

This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan and rosuvastatin. ○ Fimasartan 1. Adults The recommended dose of this drug is 30~60 milligrams once daily, with or without food. If blood pressure is not adequately controlled at this dose, it may be increased to 120 milligrams once daily. If possible, it is recommended that the drug be taken at the same time each day (e.g., in the morning). The blood pressure-lowering effect appears within 2 weeks after starting treatment, with the maximum effect occurring at approximately 8 weeks~12 weeks. 2. Older adults No initial dose adjustment is necessary in older adults 70 years of age or younger. (See section 9. Administration to older adults under Precautions for Use.) 3. Patients with renal impairment No dose adjustment is necessary in patients with mild~moderate renal impairment (creatinine clearance 30~80 mL/min). For patients with severe renal impairment (creatinine clearance < 30 mL/min), start treatment at 30 milligrams once daily and do not exceed 60 milligrams daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. Do not administer this drug to patients with moderate~severe hepatic impairment (see section 2. Patients in whom the drug must not be administered and section 10. Administration to patients with hepatic impairment under Precautions for Use). 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 milligrams once daily is recommended. (See section 3. Patients in whom the drug should be used with caution under Precautions for Use.) ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this drug at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of this drug at a dose of 40 milligrams is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to the fetus and neonate, especially during the second and third trimesters of pregnancy; therefore, it must be discontinued immediately if pregnancy is confirmed. Patients allergic to the ingredients of this medication or those who are pregnant or may become pregnant, nursing women, and patients with severe liver or kidney dysfunction should not take this medication. Patients with excessively low blood pressure or impaired kidney function, and patients with heart disease must use this medication with special caution and closely monitor their condition under doctor's instructions. This medication may cause muscle pain or weakness, and rarely serious muscle damage (rhabdomyolysis). If symptoms of muscle pain or weakness appear, inform your doctor immediately. Since liver function abnormalities may occur, it is advisable to undergo liver function tests before and during the treatment. This medication may interact with other drugs, so inform your doctor or pharmacist if you are taking other medications. Dizziness or drowsiness may occur when driving or operating machinery, so caution is advised. Keep this medication out of the reach of children and do not transfer to another container arbitrarily. In case of overdose, low blood pressure, and arrhythmias may occur, so medication dosages should be strictly followed. This medication can also be given to elderly patients, but some elderly individuals may be more sensitive to the drug, so caution is needed. It is safer not to use this medication during pregnancy or lactation, and women planning pregnancy should use appropriate contraceptive methods.

Side effects

Dyspepsia, nausea, fever, hepatitis, headache, dizziness, syncope, sedation, migraine, vomiting, upper abdominal pain, asthenia, foreign body sensation, ALT elevation, γ-GTP elevation, increased liver enzyme levels, increased white blood cell count, urinary disorders, frequent urination, cough, hyperkalemia, arthralgia, insomnia, pruritus, angioedema, decreased platelet count, elevated serum creatine phosphokinase, muscle contraction, musculoskeletal rigidity, localized urticaria, facial flushing, flushing, erectile dysfunction, constipation, abdominal pain, vomiting, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, Stevens-Johnson syndrome, eosinophilia accompanied by systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, gynecomastia, fatal and non-fatal liver failure, pharyngitis, upper respiratory infection, sputum, rhinitis, epistaxis, bronchitis, dysesthesia, numbness, tremor, hypertonia, anxiety, cognitive impairment, loss of appetite, gastroesophageal reflux, gastritis, functional gastrointestinal disorders, gastroenteritis, urinary incontinence, kidney stones, chronic renal failure, dysuria, hyperlipidemia, dyslipidemia, hypoglycemia, chest pain, low back pain, limb pain, facial edema, fatigue, fever, neck/shoulder pain, fracture, osteoporosis, myalgia, pneumonia, lung disease, hemoptysis, pulmonary granuloma, abnormal chest X-ray, panic reaction, suicide attempt, agitation, hyperthyroidism, hypothyroidism, increased TSH, benign pituitary neoplasm, tachycardia, arrhythmia, atrial fibrillation, angina, exacerbation of anemia, iron deficiency anemia, tinnitus, hearing impairment, hearing loss, pelvic inflammatory disease, vaginitis, benign prostatic hyperplasia, scrotal pain, blood pressure fluctuations, acute hepatitis, alcoholic liver disease, localized inflammation, soft tissue infection, pulmonary embolism, lymphadenopathy, wound, septal deviation, postoperative pain, heat intolerance, recurrent cancer, fall, postoperative pain, contusion

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, convex, octagonal film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP packaging ×3], 100 tablets/box [10 tablets/PTP packaging ×10], 30 tablets/box [10 tablets/Alu-Alu packaging ×3], 100 tablets/box [10 tablets/Alu-Alu packaging ×10]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.